logo
Plus   Neg
Share
Email

Alexion,Sema4 Partner In Rare Disease Diagnostics And Systems Biology

Alexion Pharmaceuticals Inc. (ALXN) and Sema4 announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. This new partnership will combine Alexion's rare disease SmartPanel analytics with Sema4's proven success in next-generation sequencing and genomic interpretation to further enable novel diagnostic and therapeutic insights into rare diseases.

Alexion and Sema4 will also collaborate in searching for and decoding rare disease "genomic shields" - a buffering mechanism that enables patients with a known disease-causing mutation in their genome to resist the manifestation of the disease.

Under the partnership, Alexion will share, research, and further refine the SmartPanel, which Sema4 will leverage to optimize the design of next-generation sequencing solutions and accelerate the interpretation of genomic and phenotypic data. Both parties will combine expertise in data science and bioinformatics to decode the network biology of target systems and research the decoding of genomic shields.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Payment solutions giant Mastercard has won a patent for a payment system linking Blockchain-based assets to fiat currency accounts. The US patent is a new method to speed up digital currency payments. The document, published by the U.S. Patent and Trademark Office or USPTO, explained that it is a method for managing fractional reserves of blockchain currency. MGM Resorts International Inc. filed federal lawsuits against more than 1,000 victims of last October's deadly mass shooting in Las Vegas in an effort to avoid liability for the incident. MGM owns the Mandalay Bay Resort, from where the gunman Stephen Paddock had launched the attack. Paddock opened fire on a large crowd at an open-air country music concert, killing 58 people. Morgan Stanley (MS) reported 43 percent growth in profit for the second quarter, reflecting strong performance in Investment Banking and sales and trading. Quarterly net revenues rose 12 percent from the prior year. Both earnings per share and revenues topped analysts' expectations.
Follow RTT